Sign in
Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2024
Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa: Results from the Phase 2b Trial
Anthony Joseph, MD
2020
The Good, the Bad, and the Best of Wnt Signaling
Kimberly A. Drenser, MD
2019
Category: Hereditary Retinal Disease & Genetics